158 related articles for article (PubMed ID: 21575258)
21. Mechanisms of Cables 1 gene inactivation in human ovarian cancer development.
Sakamoto H; Friel AM; Wood AW; Guo L; Ilic A; Seiden MV; Chung DC; Lynch MP; Serikawa T; Munro E; Oliva E; Orsulic S; Kirley SD; Foster R; Zukerberg LR; Rueda BR
Cancer Biol Ther; 2008 Feb; 7(2):180-88. PubMed ID: 18059193
[TBL] [Abstract][Full Text] [Related]
22. Methylation status of TUSC3 is a prognostic factor in ovarian cancer.
Pils D; Horak P; Vanhara P; Anees M; Petz M; Alfanz A; Gugerell A; Wittinger M; Gleiss A; Auner V; Tong D; Zeillinger R; Braicu EI; Sehouli J; Krainer M
Cancer; 2013 Mar; 119(5):946-54. PubMed ID: 23096450
[TBL] [Abstract][Full Text] [Related]
23. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
24. RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer.
Bignone PA; Lee KY; Liu Y; Emilion G; Finch J; Soosay AE; Charnock FM; Beck S; Dunham I; Mungall AJ; Ganesan TS
Oncogene; 2007 Feb; 26(5):683-700. PubMed ID: 16878154
[TBL] [Abstract][Full Text] [Related]
25. Relationship between promoter methylation & tissue expression of MGMT gene in ovarian cancer.
Shilpa V; Bhagat R; Premalata CS; Pallavi VR; Ramesh G; Krishnamoorthy L
Indian J Med Res; 2014 Nov; 140(5):616-23. PubMed ID: 25579142
[TBL] [Abstract][Full Text] [Related]
26. Frequent inactivation of a putative tumor suppressor, angiopoietin-like protein 2, in ovarian cancer.
Kikuchi R; Tsuda H; Kozaki K; Kanai Y; Kasamatsu T; Sengoku K; Hirohashi S; Inazawa J; Imoto I
Cancer Res; 2008 Jul; 68(13):5067-75. PubMed ID: 18593905
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic silencing of the LDOC1 tumor suppressor gene in ovarian cancer cells.
Buchholtz ML; Brüning A; Mylonas I; Jückstock J
Arch Gynecol Obstet; 2014 Jul; 290(1):149-54. PubMed ID: 24554348
[TBL] [Abstract][Full Text] [Related]
28. NDN is an imprinted tumor suppressor gene that is downregulated in ovarian cancers through genetic and epigenetic mechanisms.
Yang H; Das P; Yu Y; Mao W; Wang Y; Baggerly K; Wang Y; Marquez RT; Bedi A; Liu J; Fishman D; Lu Z; Bast RC
Oncotarget; 2016 Jan; 7(3):3018-32. PubMed ID: 26689988
[TBL] [Abstract][Full Text] [Related]
29. Mitogen-activated protein kinase kinase 4 (MAP2K4) promotes human prostate cancer metastasis.
Pavese JM; Ogden IM; Voll EA; Huang X; Xu L; Jovanovic B; Bergan RC
PLoS One; 2014; 9(7):e102289. PubMed ID: 25019290
[TBL] [Abstract][Full Text] [Related]
30. The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation.
Seng TJ; Low JS; Li H; Cui Y; Goh HK; Wong ML; Srivastava G; Sidransky D; Califano J; Steenbergen RD; Rha SY; Tan J; Hsieh WS; Ambinder RF; Lin X; Chan AT; Tao Q
Oncogene; 2007 Feb; 26(6):934-44. PubMed ID: 16862168
[TBL] [Abstract][Full Text] [Related]
31. IGF-II promoter specific methylation and expression in epithelial ovarian cancer and their associations with disease characteristics.
Qian B; Katsaros D; Lu L; Canuto EM; Benedetto C; Beeghly-Fadiel A; Yu H
Oncol Rep; 2011 Jan; 25(1):203-13. PubMed ID: 21109978
[TBL] [Abstract][Full Text] [Related]
32. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities.
Press JZ; De Luca A; Boyd N; Young S; Troussard A; Ridge Y; Kaurah P; Kalloger SE; Blood KA; Smith M; Spellman PT; Wang Y; Miller DM; Horsman D; Faham M; Gilks CB; Gray J; Huntsman DG
BMC Cancer; 2008 Jan; 8():17. PubMed ID: 18208621
[TBL] [Abstract][Full Text] [Related]
33. Aberrant methylation of RASSF2A in tumors and plasma of patients with epithelial ovarian cancer.
Wu Y; Zhang X; Lin L; Ma XP; Ma YC; Liu PS
Asian Pac J Cancer Prev; 2014; 15(3):1171-6. PubMed ID: 24606436
[TBL] [Abstract][Full Text] [Related]
34. Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas.
Choi YL; Kang SY; Shin YK; Choi JS; Kim SH; Lee SJ; Bae DS; Ahn G
Virchows Arch; 2006 Mar; 448(3):331-6. PubMed ID: 16315018
[TBL] [Abstract][Full Text] [Related]
35. [Hypermethylation of promoter region of RASSF1A gene in ovarian malignant epithelial tumors].
Ma L; Zhang JH; Liu FR; Zhang X
Zhonghua Zhong Liu Za Zhi; 2005 Nov; 27(11):657-9. PubMed ID: 16438885
[TBL] [Abstract][Full Text] [Related]
36. Mutation rate of MAP2K4/MKK4 in breast carcinoma.
Su GH; Song JJ; Repasky EA; Schutte M; Kern SE
Hum Mutat; 2002 Jan; 19(1):81. PubMed ID: 11754110
[TBL] [Abstract][Full Text] [Related]
37. Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer.
Lee PS; Teaberry VS; Bland AE; Huang Z; Whitaker RS; Baba T; Fujii S; Secord AA; Berchuck A; Murphy SK
Int J Cancer; 2010 Mar; 126(6):1378-89. PubMed ID: 19642140
[TBL] [Abstract][Full Text] [Related]
38. Dapper homolog 1 is a novel tumor suppressor in gastric cancer through inhibiting the nuclear factor-κB signaling pathway.
Wang S; Kang W; Go MY; Tong JH; Li L; Zhang N; Tao Q; Li X; To KF; Sung JJ; Yu J
Mol Med; 2012 Dec; 18(1):1402-11. PubMed ID: 23073659
[TBL] [Abstract][Full Text] [Related]
39. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathological implications of inactivation of RASSF1A in serous epithelial ovarian cancers.
Ma L; Guo Q; Ma Y; Liu FR; Shen XY
Eur J Gynaecol Oncol; 2009; 30(4):370-4. PubMed ID: 19761124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
